{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:33:52Z","timestamp":1791102832904,"version":"4.1.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/mcp.0b013e32833f1d00","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T06:16:29Z","timestamp":1284012989000},"page":"591-597","source":"Crossref","is-referenced-by-count":56,"title":["Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis"],"prefix":"10.1097","volume":"16","author":[{"given":"Peter A","family":"Sloane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210206","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-12-20210206","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"R4-12-20210206","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"R5-12-20210206","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"key":"R6-12-20210206","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1164\/rccm.200912-1943UP","article-title":"Update in cystic fibrosis","volume":"181","author":"Mogayzel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-12-20210206","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"R8-12-20210206","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/(SICI)1099-0496(199612)22:6<387::AID-PPUL7>3.0.CO;2-G","article-title":"Genotype-phenotype correlations in cystic fibrosis","volume":"22","author":"Kerem","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"R9-12-20210206","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.1021\/bi9004842","article-title":"Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule","volume":"48","author":"Loo","year":"2009","journal-title":"Biochemistry"},{"key":"R10-12-20210206","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1073\/pnas.0800254105","article-title":"Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function","volume":"105","author":"Serohijos","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-12-20210206","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1172\/JCI12108","article-title":"Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings","volume":"108","author":"Bronsveld","year":"2001","journal-title":"J Clin Invest"},{"key":"R12-12-20210206","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","article-title":"Cystic fibrosis: genotypic and phenotypic variations","volume":"29","author":"Zielenski","year":"1995","journal-title":"Annu Rev Genet"},{"key":"R13-12-20210206","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1074\/jbc.274.31.21873","article-title":"C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis: a novel class of mutation","volume":"274","author":"Haardt","year":"1999","journal-title":"J Biol Chem"},{"key":"R14-12-20210206","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"R15-12-20210206","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s004240050424","article-title":"Direct action of genistein on CFTR","volume":"434","author":"Weinreich","year":"1997","journal-title":"Pflugers Arch"},{"key":"R17-12-20210206","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R18-12-20210206","doi-asserted-by":"crossref","first-page":"37235","DOI":"10.1074\/jbc.M205932200","article-title":"High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening","volume":"277","author":"Ma","year":"2002","journal-title":"J Biol Chem"},{"key":"R19-12-20210206","doi-asserted-by":"crossref","first-page":"35079","DOI":"10.1074\/jbc.M303098200","article-title":"Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating","volume":"278","author":"Yang","year":"2003","journal-title":"J Biol Chem"},{"key":"R20-12-20210206","first-page":"267","article-title":"The conductance assay: a simple assay to measure \u0394F508-CFTR channel activity","volume":"32","author":"Thakerar","year":"2009","journal-title":"Ped Pulmonl Suppl"},{"key":"R21-12-20210206","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-12-20210206","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1042\/BJ20081424","article-title":"Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease","volume":"418","author":"Pasyk","year":"2009","journal-title":"Biochem J"},{"key":"R24-12-20210206","first-page":"295","article-title":"Interim results of a phase IIa study of VX-770 to evalaute safety, pharmacokinetics and biomarkers of CFTR activity in cystic fibrosis subjects with G551D.","volume":"43","author":"Accurso","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R25-12-20210206","first-page":"222","article-title":"NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator.","volume":"32","author":"Clancy","year":"2009","journal-title":"Ped Pulmonol Suppl"},{"key":"R26-12-20210206","first-page":"217","article-title":"Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR mutation.","volume":"32","author":"Boyle","year":"2009","journal-title":"Ped Pulmonol Supp"},{"key":"R27-12-20210206","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1172\/JCI119788","article-title":"In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR","volume":"100","author":"Rubenstein","year":"1997","journal-title":"J Clin Invest"},{"key":"R28-12-20210206","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"R29-12-20210206","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J Clin Invest"},{"key":"R30-12-20210206","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"R31-12-20210206","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/BJ20071420","article-title":"Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones","volume":"410","author":"Varga","year":"2008","journal-title":"Biochem J"},{"key":"R32-12-20210206","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/BJ20090389","article-title":"Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane","volume":"421","author":"Young","year":"2009","journal-title":"Biochem J"},{"key":"R33-12-20210206","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/mol.110.065862","article-title":"A chemical corrector modifies the channel function of F508del-CFTR.","volume":"78","author":"Kim Chiaw","year":"2010","journal-title":"Mol Pharmacol"},{"key":"R34-12-20210206","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1124\/mol.109.055608","article-title":"A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability","volume":"75","author":"Wellhauser","year":"2009","journal-title":"Mol Pharmacol"},{"key":"R36-12-20210206","first-page":"154","article-title":"VX-809, a CFTR corrector, increases the cell surface density of functional F508del-CFTR in preclinical models of cystic fibrosis","volume":"32","author":"Van Goor","year":"2009","journal-title":"Ped Pulmonol Supp"},{"key":"R37-12-20210206","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1124\/mol.107.040725","article-title":"Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect","volume":"73","author":"Robert","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R38-12-20210206","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1164\/rccm.200703-344OC","article-title":"Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis","volume":"177","author":"Lubamba","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R40-12-20210206","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1124\/mol.109.062679","article-title":"Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine","volume":"77","author":"Robert","year":"2010","journal-title":"Mol Pharmacol"},{"key":"R42-12-20210206","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/156802609788085241","article-title":"Inhibition of histone deacetylases: a pharmacological approach to the treatment of noncancer disorders","volume":"9","author":"Wiech","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"R43-12-20210206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nchembio.275","article-title":"Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis","volume":"6","author":"Hutt","year":"2010","journal-title":"Nat Chem Biol"},{"key":"R44-12-20210206","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"R45-12-20210206","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00018-007-7034-x","article-title":"Aminoglycoside antibiotics: old drugs and new therapeutic approaches","volume":"64","author":"Hermann","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"R46-12-20210206","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum Mol Genet"},{"key":"R47-12-20210206","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"key":"R48-12-20210206","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"key":"R49-12-20210206","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2174\/1568026033452131","article-title":"Aminoglycoside and its derivatives as ligands to target the ribosome","volume":"3","author":"Tok","year":"2003","journal-title":"Curr Top Med Chem"},{"key":"R50-12-20210206","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/jmbi.1995.0438","article-title":"The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae","volume":"251","author":"Bonetti","year":"1995","journal-title":"J Mol Biol"},{"key":"R51-12-20210206","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice","volume":"104","author":"Barton-Davis","year":"1999","journal-title":"J Clin Invest"},{"key":"R52-12-20210206","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"R53-12-20210206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1741-7015-5-5","article-title":"In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study","volume":"5","author":"Sermet-Gaudelus","year":"2007","journal-title":"BMC Med"},{"key":"R54-12-20210206","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R55-12-20210206","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"R56-12-20210206","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R58-12-20210206","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/mgme.2001.3272","article-title":"Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro","volume":"75","author":"Helip-Wooley","year":"2002","journal-title":"Mol Genet Metab"},{"issue":"Suppl A:","key":"R59-12-20210206","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/ejpn.2000.0436","article-title":"Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis","volume":"5","author":"Sleat","year":"2001","journal-title":"Eur J Paediatr Neurol"},{"key":"R60-12-20210206","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system","volume":"80","author":"Keeling","year":"2002","journal-title":"J Mol Med"},{"key":"R61-12-20210206","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations","volume":"49","author":"Wagner","year":"2001","journal-title":"Ann Neurol"},{"key":"R62-12-20210206","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr-\/- mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J Mol Med"},{"key":"R63-12-20210206","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00109-006-0045-5","article-title":"Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model","volume":"84","author":"Du","year":"2006","journal-title":"J Mol Med"},{"key":"R64-12-20210206","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.200509-1377OC","article-title":"Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials","volume":"174","author":"Wilschanski","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R65-12-20210206","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","article-title":"Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations","volume":"52","author":"Nudelman","year":"2009","journal-title":"J Med Chem"},{"key":"R66-12-20210206","first-page":"218","article-title":"Enhanced activity for translational readthrough and reduced toxicity demonstrated by the synthetic aminoglycoside NB54","volume":"32","author":"Rowe","year":"2009","journal-title":"Ped Pulmonol Supp"},{"key":"R67-12-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"R68-12-20210206","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.","volume":"47","author":"Hirawat","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R69-12-20210206","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R70-12-20210206","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"R71-12-20210206","first-page":"269","article-title":"A phase II study of PTC124 in CF patients harboring premature stop mutations","volume":"41","author":"Clancy","year":"2006","journal-title":"Ped Pulmonol Suppl"},{"key":"R73-12-20210206","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1165\/rcmb.2006-0176OC","article-title":"Restoration of W1282X CFTR activity by enhanced expression","volume":"37","author":"Rowe","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R74-12-20210206","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"key":"R75-12-20210206","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R76-12-20210206","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1073\/pnas.0909141107","article-title":"Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124","volume":"107","author":"Auld","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R77-12-20210206","doi-asserted-by":"crossref","first-page":"Symposium","DOI":"10.1016\/S1569-1993(08)60085-5","article-title":"PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF","volume":"7","author":"Wilschanski","year":"2008","journal-title":"J Cyst Fibros"}],"container-title":["Current Opinion in Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCP.0b013e32833f1d00","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:40:26Z","timestamp":1786041626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00063198-201011000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mcp.0b013e32833f1d00","relation":{},"ISSN":["1070-5287"],"issn-type":[{"value":"1070-5287","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}